Mavoglurant is under development by Novartis and is currently in Phase II and Phase III clinical trials. If successful, it would be the first drug to treat the underlying disorder instead of the symptoms of fragile X syndrome.
Mavoglurant is also in Phase II clinical trials for Levodopa-induced dyskinesia.
In 2007, Norvartis had conducted a clinical study to assess its ability of reducing cigarette smoking, but no results had been published up till now.
Currently Novartis is conducting a clinical trial with this drug on Obsessive Compulsive Disorder.
^Levenga, J; Hayashi, S; De Vrij, FM; Koekkoek, SK; Van Der Linde, HC; Nieuwenhuizen, I; Song, C; Buijsen, RA et al. (2011). "AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome". Neurobiology of disease42 (3): 311–7. doi:10.1016/j.nbd.2011.01.022. PMID21316452.|displayauthors= suggested (help)
^Jacquemont, S.; Curie, A.; Des Portes, V.; Torrioli, M. G.; Berry-Kravis, E.; Hagerman, R. J.; Ramos, F. J.; Cornish, K. et al. (2011). "Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome is Associated with Differential Response to the mGluR5 Antagonist AFQ056". Science Translational Medicine3 (64): 64ra1. doi:10.1126/scitranslmed.3001708. PMID21209411.|displayauthors= suggested (help)